SEC Comment Letter 0000000000-24-011896 to Athira Pharma, Inc. (ATHA) (CIK 0001620463) (LONA)
Athira Pharma, Inc. (ATHA) (CIK 0001620463)
Date: Oct. 24, 2024 · CIK: 0001620463 · Accession: 0000000000-24-011896
AI Filing Summary & Sentiment
File numbers found in text: 333-282738
Letter
October 24, 2024 Mark Litton President and Chief Executive Officer Athira Pharma, Inc. 18706 North Creek Parkway, Suite 104 Bothell, WA 98011 Re:Athira Pharma, Inc. Registration Statement on Form S-3 Filed October 21, 2024 File No. 333-282738 Dear Mark Litton: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Bryan D. King
Show Raw Text
October 24, 2024
Mark Litton
President and Chief Executive Officer
Athira Pharma, Inc.
18706 North Creek Parkway, Suite 104
Bothell, WA 98011
Re:Athira Pharma, Inc.
Registration Statement on Form S-3
Filed October 21, 2024
File No. 333-282738
Dear Mark Litton:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Bryan D. King